ES2283127T3 - Nuevos peptidos antidiabeticos. - Google Patents

Nuevos peptidos antidiabeticos. Download PDF

Info

Publication number
ES2283127T3
ES2283127T3 ES99939073T ES99939073T ES2283127T3 ES 2283127 T3 ES2283127 T3 ES 2283127T3 ES 99939073 T ES99939073 T ES 99939073T ES 99939073 T ES99939073 T ES 99939073T ES 2283127 T3 ES2283127 T3 ES 2283127T3
Authority
ES
Spain
Prior art keywords
baselineskip
ala
ser
xaa
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99939073T
Other languages
English (en)
Spanish (es)
Inventor
Nigel Robert Arnold Beeley
Kathryn S. Prickett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2283127T3 publication Critical patent/ES2283127T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES99939073T 1998-08-21 1999-08-09 Nuevos peptidos antidiabeticos. Expired - Lifetime ES2283127T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US138056 1998-08-21
US09/138,056 US6087334A (en) 1998-08-21 1998-08-21 Anti-diabetic peptides

Publications (1)

Publication Number Publication Date
ES2283127T3 true ES2283127T3 (es) 2007-10-16

Family

ID=22480238

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99939073T Expired - Lifetime ES2283127T3 (es) 1998-08-21 1999-08-09 Nuevos peptidos antidiabeticos.

Country Status (9)

Country Link
US (1) US6087334A (enExample)
EP (1) EP1104438B1 (enExample)
JP (1) JP2002523424A (enExample)
AT (1) ATE354590T1 (enExample)
AU (1) AU766545B2 (enExample)
CA (1) CA2337971C (enExample)
DE (1) DE69935229T2 (enExample)
ES (1) ES2283127T3 (enExample)
WO (1) WO2000011029A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2001293557A1 (en) * 2000-09-19 2002-04-02 University Of Toronto New inhibitors of iapp fibril formation and uses thereof
EP1474164B1 (en) * 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
JP2008500281A (ja) * 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
KR20070083815A (ko) * 2004-10-26 2007-08-24 론자 아게 고체상 합성에서 ｓ-알킬-술페닐 보호기
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CN101193626A (zh) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
NZ578299A (en) 2005-03-31 2010-03-26 Amylin Pharmaceuticals Inc Amylin and amylin agonists for treating schizophrenia
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
US8309522B2 (en) 2007-02-05 2012-11-13 Amylin Pharmaceuticals, Llc Neuromedin and FN-38 peptides for treating psychiatric diseases
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
DK2211842T3 (en) * 2007-10-24 2015-09-21 Mannkind Corp An inhalable dry powder formulation COMPREHENSIVE GLP-1 FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DIABETES BY pulmonary delivery
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
WO2009158412A2 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
UA104866C2 (uk) * 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101673042B1 (ko) * 2009-03-12 2016-11-04 키바이오사이언스 아게 당뇨병 및 대사 증후군의 치료
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
EP2841089A4 (en) 2012-04-03 2016-03-16 Univ Boston COMPOSITIONS, PROCESSES AND ASSAYS WITH AMYLIN OR AMLYANANALOGA FOR ABETA PEPTIDE-MEDIATED ILLNESSES
CA3098386C (en) 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
AU2014232954B2 (en) 2013-03-15 2018-08-09 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
MX369136B (es) 2013-03-15 2019-10-30 Mannkind Corp Composiciones de dicetopiperazina microcristalina y metodos.
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
ES2890600T3 (es) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
TW201625671A (zh) * 2014-09-04 2016-07-16 諾佛 儂迪克股份有限公司 新穎澱粉素及降鈣素受體促效劑
CA2962642A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel .alpha.4.beta.7 peptide monomer and dimer antagonists
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
MA58373B1 (fr) 2020-01-15 2025-07-31 Janssen Biotech, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2023005994A (es) 2020-11-20 2023-08-11 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23.
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
US5965528A (en) * 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
CA2120131A1 (en) * 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
PL307138A1 (en) * 1993-05-12 1995-05-02 Univ Cincinnati Amyline antagonists and agonists
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists

Also Published As

Publication number Publication date
CA2337971A1 (en) 2000-03-02
ATE354590T1 (de) 2007-03-15
EP1104438A2 (en) 2001-06-06
WO2000011029A2 (en) 2000-03-02
JP2002523424A (ja) 2002-07-30
AU5343099A (en) 2000-03-14
WO2000011029A3 (en) 2000-06-22
DE69935229D1 (de) 2007-04-05
AU766545B2 (en) 2003-10-16
EP1104438B1 (en) 2007-02-21
DE69935229T2 (de) 2007-11-08
US6087334A (en) 2000-07-11
CA2337971C (en) 2011-04-26
HK1038025A1 (en) 2002-03-01

Similar Documents

Publication Publication Date Title
ES2283127T3 (es) Nuevos peptidos antidiabeticos.
ES2291017T3 (es) Efectos inotropicos y diureticos de la exendina y glp-1.
ES2278589T3 (es) Excendinas destinadas a la inhibicion de glucagon.
ES2319936T3 (es) Metodos para regular la motilidad gastrointestinal.
RU2130463C1 (ru) Аналог-агонист амилина, его фармацевтически приемлемые соли, композиция, проявляющая свойства агониста амилина
US7928065B2 (en) Methods of treatment using exendin peptides or GLP-1 peptides
US7220721B1 (en) Exendin agonist peptides
ES2294822T3 (es) Compuestos novedosos de agonistas de exendina.
ES2244416T5 (es) Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
US8759291B2 (en) Methods of treatment using exendin peptides or GLP-1 peptides
JP2001513512A (ja) 新規なエキセンディン作動剤化合物
US7101853B2 (en) Method for treating or preventing gastritis using amylin or amylin agonists
ES2356595T3 (es) Nuevos compuestos de actividad mixta de la amilina.
ES2244010T3 (es) Metodos y composiciones para el tratamiento del dolor.
US6936584B1 (en) Mixed amylin activity compounds
AU2006252240B2 (en) Inotropic and diuretic effects of exendin and GLP-1
HK1038025B (en) Novel anti-diabetic peptides